Overview
The Issels treatment, also known as the Issels protocol or Issels therapy, is an alternative cancer treatment developed in the 1950s by German physician Dr. Josef Issels (1900‑1998). It combines surgery, conventional radiotherapy, selective chemotherapy, hyperthermia, immunotherapy, and a strict regimen of diet, exercise, and psychosocial support. The approach is predicated on the belief that cancer arises from a “defect of the immune system” and that strengthening the body’s natural defenses can lead to tumor regression.
Historical development
- 1920s‑1950s: Dr. Issels began treating patients with a combination of conventional and experimental modalities, emphasizing “total body treatment” rather than localized surgery alone.
- 1970s‑1980s: The Issels Clinic in Lörrach, Germany, was established, attracting patients from Europe and North America.
- 1990s–present: The clinic continued to offer the protocol, and a limited number of publications by Issels and co‑authors described case series and observational data.
Key components of the protocol
| Component | Description |
|---|---|
| Surgery | Removal of primary tumors when feasible, often with extended margins. |
| Radiotherapy | Conventional external‑beam radiation, sometimes combined with hyperthermia (heating of tissue to 41–43 °C) to enhance radiosensitivity. |
| Chemotherapy | Low‑dose, metronomic chemotherapy regimens aimed at minimizing toxicity while targeting angiogenesis. |
| Immunotherapy | Use of cytokine preparations (e.g., interferon‑α, interleukin‑2) and autologous vaccines derived from the patient’s own tumor tissue. |
| Hyperthermia | Local or regional heating applied alongside radiation or chemotherapy. |
| Lifestyle program | Structured diet (often low‑fat, high‑vegetable), regular physical activity, stress‑reduction techniques, and psycho‑social counseling. |
Scientific evaluation
- Clinical evidence: The primary data consist of small, uncontrolled case series published in peer‑reviewed journals (e.g., British Journal of Cancer 1995; Medical Oncology 1998). These studies lack randomization, control groups, and standardized outcome measures, limiting their interpretability.
- Systematic reviews: Reviews by oncology societies and independent researchers have concluded that the evidence does not meet the methodological standards required to establish efficacy. No randomized controlled trials (RCTs) demonstrating a survival benefit have been reported.
- Safety: Reported adverse events are generally those associated with the individual components (e.g., chemotherapy toxicity, radiation side effects). The combination of multiple modalities may increase cumulative toxicity, but systematic safety data are lacking.
Regulatory and professional stance
- Germany: The Issels Clinic operates under German medical law, offering the protocol as a “complementary” service. Treatments are not covered by statutory health insurance; patients pay out‑of‑pocket.
- United States: The FDA has not approved any product or regimen bearing the Issels name. The American Cancer Society and the National Cancer Institute categorize the Issels treatment as an unproven alternative therapy.
- Professional societies: The European Society for Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO) list the Issels protocol among “non‑evidence‑based” cancer therapies and advise patients to rely on standard-of-care treatments supported by high‑quality clinical trials.
Criticism and controversies
- Lack of rigorous data: Critics emphasize the absence of RCTs and the reliance on anecdotal success stories.
- Potential for delay: Patients who pursue the Issels protocol exclusively may postpone or forego proven standard therapies, potentially affecting outcomes.
- Cost: The comprehensive nature of the program can be financially burdensome, with limited reimbursement options.
Current status
As of 2024, the Issels treatment remains offered primarily through the original clinic in Lörrach and a limited number of affiliated centers. Interest persists among a subset of patients seeking integrative or “holistic” approaches, but mainstream oncology continues to regard it as lacking sufficient scientific validation.
References (selected)
- Issels RD, et al. “A non‑randomized trial of the Issels multimodal therapy in patients with locally advanced breast cancer.” British Journal of Cancer 71, 1995: 1039‑1045.
- Höcker B, et al. “Hyperthermia combined with radiotherapy and chemotherapy in the Issels protocol: clinical observations.” Medical Oncology 15, 1998: 89‑96.
- American Cancer Society. “Cancer‑treatment‑related side effects: Complementary and Alternative Medicine.” 2023.
- European Society for Medical Oncology. “Guidelines for the Use of Integrative Oncology.” 2022.
Note: The information presented reflects the current state of publicly available, peer‑reviewed, and regulatory sources up to July 2026.
